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Abstract Granulocyte colony-stimulating factor (G-CSF)
is an activator of neutrophil granulocytes. Neutrophil
extracellular traps are a defensive mechanism consisting of
neutrophils, platelets, DNA, histones and antimicrobial
proteins. This study was performed to determine whether
G-CSF increases histone-complexed DNA in the plasma of
healthy volunteers. In total, 51 healthy volunteers (25
males and 26 females) were treated with G-CSF (18 with
300 lg single dose i.v., 27 with 5 lg/kg s.c. for 4 days)
and six participants received a placebo. Histone-complexed
DNA was measured by enzyme immunoassay in plasma
samples at predefined time points (0, 2, 4, 6, 24 h after
single dose, day 1, day 2 and day 5 after repeated doses).
Histone levels were quantified by Western blotting. A
single dose of G-CSF rapidly increased hc-DNA by about
50 % (p\ 0.05 for 2–24 h). After repeated doses the
increase was even more pronounced: hc-DNA increased by
about 50 % (3.0 ± 0.9, p\ 0.001 after 24 h and about
fourfold after 96 h (p\ 0.001)). A statistical significant
increase in histone levels was detected as early as 4 h after
G-CSF injection (0.43 ± 0.2 vs. 1.08 ± 0.3 lg/ml;
p = 0.034). In the placebo group no significant changes
occurred. Moreover, significantly higher levels of hc-DNA
were measured in male compared to female subjects
(226 ± 43 vs. 84 ± 19, p\ 0.001). G-CSF injection sub-
stantially increases hc-DNA levels in healthy volunteers.
There is a significant gender difference in hc-DNA at the
baseline.
Keywords G-CSF  Histones  NETs  Gender 
Neutrophils
Introduction
Granulocyte colony-stimulating factor (G-CSF) not only
stimulates the growth and proliferation of hematopoietic
progenitor cells, but also activates mature granulocytes.
Binding of G-CSF to its receptor prolongs the lifespan of
granulocytes, enhances the phagocytic activity and induces
degranulation of preformed and stored defensive sub-
stances and modulators of the immune system [1–3].
Endogenous plasma levels of G-CSF rise during infections,
experimental endotoxemia [4, 5] or neutropenia [6].
Recently a new defensive mechanism was discovered. In
a process called ‘‘NETosis’’ neutrophil extracellular traps
(NETs) are formed. In short, stimulation of neutrophils
leads to an interaction with the endothelium and to chro-
matin decondensation by enzymes (i.e., neutrophil elastase,
myeloperoxidase or peptidyl arginine deiminase type IV).
Neutrophils then release decondensated DNA, associated
antimicrobial factors and histones. These ‘‘traps’’ are ready
to catch and attack pathogens [7]. Hence, histone-com-
plexed DNA (hc-DNA) increases in the blood of patients
suffering from severe sepsis [8]. Also erythrocytes and
blood platelets are associated with NETs in blood vessels.
As NETs also seem to play a pathogenic role in deep
venous thrombosis, they may constitute an important link
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between inflammation and thrombosis [9, 10]. G-CSF
injection markedly enhances platelet aggregation and
shear-dependent platelet function [11, 12].
In a mouse model investigating the prothrombotic state
of cancer patients the involvement of G-CSF in NET for-
mation was demonstrated for the first time [13]. Thus, we
hypothesized that injection of G-CSF may increase plasma
levels of hc-DNA in healthy volunteers.
Materials and methods
Study design
Written informed consent was obtained from all study
participants before study entry. The study protocol was
approved by the Independent Ethics Committee of the
Medical University of Vienna, and the trial was registered
in a public database (EudraCT No. 2006-005582-18,
2008-004550-32). The study was conducted in accordance
with the good clinical practice guidelines and the Decla-
ration of Helsinki. The trial took place at the Medical
University of Vienna, Department of Clinical Pharmacol-
ogy, and was conducted between December 8, 2006, and
June 17, 2009.
Healthy men and women between 18 and 55 years, with
a body weight B96 kg, were included in the study. All
participants signed an informed consent form before any
trial-related activity was performed. All female subjects
with childbearing potential performed a negative urine
pregnancy test before inclusion. All subjects were non-
smokers with normal laboratory values and normal findings
in their medical history.
Exclusion criteria contained known spleen enlargement,
hypersensitivity to any of the formulations’ ingredients,
clinically relevant abnormal laboratory values, use of any
medication during 2 weeks before the start of the study, a
clinically relevant illness within 3 weeks before the start of
the study, a recent infection within 1 week, skin abnor-
malities at the injection site or any other medical condition
deemed relevant by the principal investigator.
The trial took place at the Department of Clinical
Pharmacology of the Medical University of Vienna. The
trial was performed to investigate biosimilarity between
two G-CSF formulations. In the trial protocol, storage of
plasma samples for academic purposes was planned before
the initiation of the trial. In one part of the project, healthy
volunteers received 300 lg of G-CSF intravenously (i.v.).
In another part, a double blind, randomized, active and
placebo-controlled, parallel group trial, healthy volunteers
were randomized to receive 5 lg/kg G-CSF subcuta-
neously or a placebo on four consecutive days. This dose
was chosen with regard to the primary endpoint of the
trials, the absolute neutrophil count. Increasing the G-CSF
dose to 10 lg/kg bodyweight does not have a major
influence on the absolute neutrophil count [14], but
increases the amount of CD34? cells in peripheral blood.
However, CD34? cells were only a secondary endpoint in
these trials. Thus, we decided not to further increase the
dose to reduce potential hazards to healthy volunteers.
Furthermore, this dose should be sufficient to activate
peripheral neutrophils.
Blood sampling
Samples were drawn using intravenous catheters placed in
an appropriate antecubital vein. After discarding the first
2 mm of blood, blood was drawn into sterile blood tubes
anticoagulated with 3.8 % sodium citrate or EDTA (
Vacuette). Additionally intravenous catheters were flushed
with 0.9 % sodium chloride solution after each sampling
time point. Blood samples were drawn before administra-
tion and at predefined time points thereafter (0, 2, 4, 6, 24 h
and days 1, 2 and 5). Blood samples were then centrifuged
at 2000g at 4 C for 15 min. Plasma was stored at -80 C
until analyzed.
Biomarker assays
We performed enzyme immunoassays to detect blood
levels of hc-DNA. Cell death detection ELISA plus kit
(Roche) uses monoclonal mouse antibodies against his-
tones (antihistone-biotin, clone H11-4) and single- and
double-stranded DNA (anti-DNA POD, cloneMCA-33) to
detect apoptotic or necrotic cells in plasma or cell culture
supernatants. In short, histone-complexed mono- and
oligonucleosomes are quantified. The presented values are
light absorbance values (405 nm) directly derived from the
described assay and therefore arbitrary units. The assay
was performed according to the manufacturers’ instruc-
tions. Histone levels were quantified by Western blotting
using antihistone H3 antibodies (Abcam) and calculated
using human recombinant histone H3 as standard, as
described previously [15]. We performed these tests in a
smaller number of samples in collaboration with the
University of Liverpool. Measurements were taken in
samples of five randomly chosen patients of each study.
Statistical analysis
All data are expressed as mean ± standard error of the
mean (SEM) unless otherwise stated. For reasons of
robustness we have chosen nonparametric tests. Within-
group differences were tested overall by Friedman
ANOVA, and pairwise comparisons were made by Wil-
coxon signed rank test. Results of histone quantification
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were compared by pairwise T tests after logarithmic
transformation. Nonparametric tests were not applied
because of the small sample size. Where applicable,
baseline data were compared with the nonparametric
Kruskal–Wallis test, followed by a U test. Correlations
were performed by the nonparametric Spearman test. A
two-tailed p\ 0.05 was considered statistically significant.
All statistical calculations were performed using commer-




We analyzed samples of six participants receiving a pla-
cebo, 27 participants treated with 5 lg/kg body weight for
four consecutive days and 18 participants receiving a single
dose of 300 lg G-CSF intravenously.
Baseline characteristics of participants of each study are
presented in Table 1. No significant differences can be
found between the placebo group and the G-CSF groups
with regard to height, weight, body mass index, neutrophil
counts, platelet counts or the level of C-reactive protein.
Histone-complexed DNA
A single dose of 300 lg G-CSF significantly increased hc-
DNA in the plasma of healthy volunteers 2, 4, 6 and 24 h
after the intravenous injection (p = 0.003 for overall test-
ing with Friedman ANOVA; compared to baseline, Table 2
with pairwise comparison). Significantly higher levels of
hc-DNA were found at each time point after the G-CSF
administration compared to the baseline levels. However,
after 2 h there was no further increase in the amount of
circulating hc-DNA.
Subcutaneous injection of 5 lg/kg G-CSF time depen-
dently increased plasma levels of hc-DNA after 24 and
96 h compared to the baseline (p\ 0.001 for overall test-
ing with Friedman ANOVA, compared to baseline, Table 3
with pairwise comparison), and the increase after 96 h was
more pronounced (p\ 0.001; 24 vs. 96 h).
In the placebo group no significant changes in any of the
investigated parameters could be detected (P = 0.85)
(Table 3).
Histone quantification
At the baseline we measured total histone levels of
0.43 ± 0.20 lg/ml, which increased to 1.71 ± 0.54 lg/ml
(p = 0.088) 2 h and 1.08 ± 0.30 lg/ml (p = 0.034) 4 h
after infusion of 300 lg G-CSF.
In the study investigating effects of four daily doses of
G-CSF we detected 1.39 ± 0.37 lg/ml, 24 h after the first
G-CSF injection 1.24 ± 0.26 lg/ml and on day five, 24 h
after the fourth injection of 5 lg/kg G-CSF, 2.16 ±
0.62 lg/ml. There was no significant difference between
Table 1 Presented are
demographic data of all study
participants (mean ± SD)






Gender m/f 9/9 15/12 1/5 0.32
Age (years) 30 ± 2 29 ± 1 26 ± 2 0.57
Height (cm) 171 ± 2 173 ± 2 168 ± 3 0.34
Weight (kg) 69 ± 3 70 ± 2 63 ± 7 0.43
Body mass index (kg/m2) 23.8 ± 0.8 23.3 ± 0.8 22 ± 1.6 0.76
Neutrophil count (G/L) 3.2 ± 0.3 3.0 ± 0.2 3.5 ± 0.2 0.28
Platelet count (G/L) 228 ± 12 229 ± 11 244 ± 17 0.62
C-reactive protein (mg/dl) 0.2 ± 0.1 0.4 ± 0.2 0.2 ± 0.1 0.50
No significant differences were found between groups
All values are presented as mean ± SEM, and p values are the results of nonparametric tests
Table 2 Levels of histone-complexed DNA in the plasma of study
participants before and 2, 4, 6 and 24 h after a single intravenous
injection of G-CSF are presented
Mean SEM IQR p value
Baseline 197 32 69–299
2 h 290 43 171–357 0.006*
4 h 287 46 133–357 0.02*
6 h 293 35 142–435 0.001*
24 h 292 50 126–484 0.006*
Values presented resemble baseline values and time after G-CSF
administration




these measurements. However, a borderline increase
between days two and five (p = 0.064) was found.
Gender differences
To examine potential gender differences we performed a
pooled analysis of blood samples taken at the baseline.
Samples of 26 female and 25 male healthy volunteers were
analyzed. We detected significantly higher amounts of hc-
DNA in male subjects than in female subjects (226 ± 43 in
male vs. 84 ± 19 in female subjects, p\ 0.001).
The sample size of the subgroup receiving a single dose
was probably too limited to demonstrate significant gender
differences between nine male and nine female volunteers
(232 ± 46 vs. 161 ± 42, p = 0.34). In contrast, the trial
investigating daily doses of 5 lg/kg G-CSF demonstrated
marked gender differences at all times (p\ 0.002; Fig. 1;
n = 15 male and 12 female subjects).
Within female subjects levels of hc-DNA rose from
baseline values of 50 ± 14 to 120 ± 48 and 299 ± 29
after 24 and 96 h (p = 0.012, and p = 0.002, respectively),
whereas in male subjects baseline values of 234 ± 67 rose
to 319 ± 76 and 838 ± 148 after 24 and 96 h (p = 0.005
and p = 0.001, respectively) (Fig. 1).
Correlations
Although both hc-DNA and neutrophils increased over
time, an exploratory correlation analysis including all
measured values revealed only a weak correlation within
each study. In the single dose study the correlation coef-
ficient was 0.272 (p = 0.009), and in the study of multiple
doses the correlation coefficient was 0.310 (p = 0.005).
Figure 2 shows that there is a time lag between the increase
in neutrophils with almost a plateau after 24 h and the
maximum levels of hc-DNA.
Discussion
This trial demonstrates (1) that infusion of a single dose of
300 lg G-CSF significantly increases hc-DNA in the
plasma of healthy volunteers, (2) that this increase is even
more pronounced after injection of four daily doses of
G-CSF, (3) that there is a significant difference in serum
levels of hc-DNA between male and female subjects, at the
baseline and after injection of G-CSF, and (4) histone
plasma levels significantly increase as early as 4 h after a
single G-CSF injection.
Neutrophils of mice receiving daily G-CSF as well as
neutrophils of mice bearing G-CSF-producing cancer cells
are predisposed to generate NETs after activation [13]. Our
findings support these results and underline the involve-
ment of G-CSF in hc-DNA release in humans. Additionally
we were able to show that a single dose of G-CSF is suf-
ficient to rapidly increase levels of hc-DNA in plasma.
Levels of G-CSF are elevated during infections [6].
Usually this is explained by the need for a greater number
of neutrophils, and infection-associated leukocytosis is the
result of this increase. However, among its specific roles,
the cell-activating properties of G-CSF are of special
interest in this study. Binding of G-CSF to its receptor
leads to internalization of the receptor and to an immediate
activation of neutrophils. Consecutively activated neu-
trophils release the contents of their preformed granules
and leave the blood stream into the surrounding tissue. An
immediate but transient drop in the absolute neutrophil
Fig. 1 Gender differences in histone-complexed DNA before and
after 4 daily doses of 5 lg/kg body G-CSF. Although in male and in
female subjects a significant increase in hc-DNA after single (day 2)
or multiple (day 5) doses of G-CSF can be detected, a significant
gender difference can be identified. Female subjects have significantly
lower hc-DNA levels at the baseline, on day 2 and on day 5,
compared to men. Presented data are means ± SEM
Table 3 Levels of histone-complexed DNA after four consecutive
daily doses of 5 lg/kg body weight and the results of the placebo
group
Mean SEM IQR p value
0 h 152 41 30–194
Placebo 34 10 20–54
24 h 231 51 74–272 \0.001
Placebo 77 37 23–59 0.4
96 h 598 97 255–867 \0.001
Placebo 55 20 15–94 0.6
Values resemble baseline values (0 h) and time after daily G-CSF
doses. p values are the results of nonparametric tests versus baseline
values
SEM standard error of the mean, IQR interquartile range
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count in peripheral blood can be observed shortly after
injection of G-CSF [3, 17].
A recently discovered defensive mechanism of neu-
trophil granulocytes called ‘‘NETosis’’ is described as a
cell death distinct from apoptosis and necrosis. NETosis is
a cell death program that results in the expulsion of
decondensated DNA from neutrophil granulocytes along-
side the exertion of other preformed substances stored in
various granules within the cell. This DNA builds loose
congregates of neutrophils, platelets, erythrocytes, and
antimicrobial substances as well histones that entangle the
pathogens and possibly kill them [7, 18]. Interestingly,
Staphylococcus aureus is able to produce enzymes, which
degrade these NETs and escape this defensive mechanism
[19].
In this study we measured hc-DNA before and after
G-CSF administration. Although we did not further iden-
tify the origin of this circulating extracellular DNA, it
seems likely that the DNA is of neutrophil origin. An
increase in plasma myeloperoxidase after G-CSF treatment
was reported previously. This supports our hypothesis, as
this enzyme is not just of neutrophil origin, but can also be
found in NETs [7, 20]. The absolute neutrophil count rises
after G-CSF injection. However, the correlation between
the neutrophil count and the DNA overall was rather weak
(correlation coefficient 0.310 and 0.272, respectively). This
indicates that the amount of hc-DNA in the plasma is not
merely depending on the number of circulating neutrophils
itself, but on the number of activated neutrophils. Our
results of the substudy investigating the effect of a single
intravenous dose of 300 lg/kg G-CSF underline this
observation. Two hours after injection we found a signifi-
cant increase in hc-DNA although neutrophil numbers did
not rise notably. In contrast, 24 h after this single dose, the
amount of hc-DNA did not further increase compared with
the level at 2 h post-dose, although the number of circu-
lating neutrophils rose almost fivefold (Fig. 2). This is in
accordance with several studies demonstrating rapid acti-
vation of preformed neutrophils after G-CSF administra-
tion [3, 21].
Abrams et al. pointed out that histones play a patho-
physiological role in patients suffering from trauma, but
also from necrotizing pancreatitis or sepsis. In their mouse
model, infusion of histones led to an increase in thrombin–
antithrombin complexes indicating activation of coagula-
tion. Furthermore in 52 trauma patients circulating histone
levels were correlated with sequential organ failure
assessment (SOFA) scores [15]. In our study, all measured
histone levels were low and within the normal range of
healthy volunteers. Abrams et al. reported median histone
levels of 2.3 lg/ml in healthy volunteers, but 28.6 lg/ml in
trauma patients. The increases in our study were small, and
statistical findings may also be due to the small sample
size. On the other hand G-CSF injection did also not lead to
a relevant activation of blood coagulation (see below).
Moreover, repeated doses of G-CSF increased C-reactive
protein levels approximately twofold (0.23–0.51 mg/dl).
However, this increase is still within the limits of the
normal range [12]. Considering these findings, the increase
in hc-DNA may be more likely to be a consequence of an
increase in circulating DNA rather than an increase in
histones.
Beside neutrophils, the activation of the endothelium
and endothelial damage may be the source of hc-DNA.
G-CSF injection also leads to endothelial activation as
demonstrated by Stroncek et al. However, in their study
they administered 10 lg/kg G-CSF for 5 days and showed
an increase in E-selectin of 78 ± 34 % after 5 days [22]. A
a b
Fig. 2 a Time course of hc-DNA and ANC after 300 lg G-CSF
single dose, correlation coefficient 0.272, b time course of hc-DNA
and ANC after daily 5 lg/kg G-CSF, correlation coefficient 0.310.
The correlation between hc-DNA and neutrophil granulocyte count
over time is small. This indicates that the level of plasma hc-DNA is
not depending on the neutrophil count, but may be more dependent




similar regimen was used in another study that also
demonstrated increases of E-selectin after 5 days [20].
Thus, the pronounced increase of hc-DNA on day five may
also be attributable to endothelial activation. On the other
hand, no data exist yet investigating immediate effects of a
single G-CSF dose on the endothelium. Finally, we cannot
exclude that both, the endothelium and neutrophils, may
contribute to that rise, which is a limitation of this trial.
Interestingly, there was a significant difference in the
levels of hc-DNA between male and female healthy vol-
unteers, which is in contrast to the results of Tillack et al.
[23]. In their work, Tillack et al. detected gender differ-
ences in patients diagnosed with remittent-relapsing mul-
tiple sclerosis, but not in healthy volunteers or any other
patient group under investigation. We found significantly
higher levels of plasma hc-DNA in male than in female
subjects in the pooled analysis of baseline values (26
females and 25 males) and within the substudy of healthy
volunteers receiving consecutive G-CSF doses.
The role and importance of NETs and circulating
extracellular DNA in the pathophysiology of thrombosis
are currently intensively investigated [24–26]. A single
dose of G-CSF increases von Willebrand factor activity
slowly by *60 % which may in part contribute to accel-
erated platelet plug formation under high shear rates [11].
While the effects of G-CSF on platelet aggregation are
pronounced and clear-cut, the G-CSF-induced increase in
coagulation appears to be limited in vivo. Multiple doses of
G-CSF enhance platelet aggregation [12]. Despite a tran-
sient[ fivefold increase in whole-blood TF-mRNA 4 h
after a single G-CSF dose, and a somewhat accelerated
clotting time in rotational thromboelastometry, G-CSF
increases prothrombin fragment levels only mildly
(*30 %) and transiently in the blood of healthy volunteers
[11]. Furthermore G-CSF at doses of 10 lg/kg body weight
for 5 days also increased the tissue factor-dependent
coagulation [27]. In striking contrast, D-dimer levels do not
change after G-CSF in healthy volunteers [11, 12], arguing
against relevant induction of clotting in vivo. Thus, the
G-CSF-enhanced release of hc-DNA does not go along
with a clinically relevant extent of in vivo thrombin gen-
eration. It was proposed that the main driver for thrombin
generation may be the histone content of NETs and that
these histones need to be dismantled, i.e., by the addition of
DNAse, to trigger thrombin generation [16]. This was also
demonstrated for endothelial damage, as intact nucleo-
somes do not exert toxic effects. When these nucleosomes
were degraded, by incubation with serum or by sonication,
toxic effects on endothelial cells were detected [28]. Thus,
it is conceivable that G-CSF may lead to NET formation,
but histones within NETs remain shielded and no relevant
induction of clotting results.
Furthermore, usually only healthy people before stem
cell harvest or patients during neutropenia, which is fre-
quently accompanied by thrombocytopenia, are treated
with G-CSF. Thus, thrombotic events are generally rare
and more of episodic character. A large trial investigating
adverse events in peripheral blood stem cell donors found
no increased risk of thrombosis after mobilization with
G-CSF compared to bone marrow donors without stem cell
mobilization [29]. Finally, pattern recognition receptors for
extracellular DNA have been identified and C-reactive
protein levels are known to rise after multiple doses of
G-CSF in healthy volunteers [12, 30]. Thus, the increased
hc-DNA levels may contribute to the activation of the
inflammatory cascade after treatment with G-CSF. To what
extent hc-DNA contributes to this inflammatory response
remains unclear due to its complexity and needs to be
further elucidated by additional studies.
Conclusion
Injection of single and multiple doses of G-CSF increased
levels of hc-DNA significantly. Interestingly, a gender
difference with lower levels of hc-DNA in female than in
male subjects was detected.
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